vorinostat has been researched along with Adenocarcinoma, Alveolar in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Owonikoko, TK | 1 |
| Ramalingam, SS | 1 |
| Kanterewicz, B | 1 |
| Balius, TE | 1 |
| Belani, CP | 1 |
| Hershberger, PA | 1 |
1 other study available for vorinostat and Adenocarcinoma, Alveolar
| Article | Year |
|---|---|
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.
Topics: Acetylation; Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemothera | 2010 |